Advertisements
Omoseebi et al
|
Greener Journal of Medical Sciences Vol. 11(2), pp. 201-211, 2021 ISSN: 2276-7797 Copyright ©2021, the copyright of this article is retained by the author(s) |
|
Genotyping of Human Papilloma Virus (HPV) in Cervical Cancer at the Federal Teaching Hospital Ido-Ekiti, Ekiti State, Nigeria
Omoseebi O1,2; Okiki P.A3; Obajuluwa A.O3; Erinomo O.O1,2
1 Department of Morbid Anatomy and Histopathology, Federal Teaching Hospital Ido Ekiti, Ekiti State, Nigeria
2 Department of Anatomic Pathology and Forensic Medicine, College of Medicine and Health Sciences, Afe Babalola University Ado Ekiti, Ekiti State, Nigeria
3 Department of Biological Sciences, College of Sciences, Afe Babalola University, Ado-Ekiti, Ekiti State, Nigeria
|
ARTICLE INFO |
ABSTRACT |
|
Article No.: 110821116 Type: Research |
Background: Human papillomavirus (HPV) is the main causative agent of cervical cancer and 99.7% of cervical cancer has been attributed to infection by the virus. Cervical cancer is a common cancer in women in sub-Saharan Africa and it remains a serious public health issue. This study was carried out to determine the genotypes of HPV in archival specimen of cervical cancer cases at the Federal Teaching Hospital Ido-Ekiti (FTHI), Ekiti state, Nigeria. Methods: The materials for this study consisted of paraffin embedded tissue blocks, Haematoxylin and Eosin (H&E) stained slides, hospital request forms, patients case notes and duplicate copies of histopathology reports of histologically-diagnosed cervical cancer patients at the Morbid Anatomy and Histopathology Department of FTHI between January 2017 and December 2019. DNA extraction and quantification was done. Real time PCR (qPCR) was done to determine different types of Human papilloma virus present in archival specimens using specific primers (4X HPV 28 A TOM (Primer A) and 4X HPV 28 B TOM (Primer B). Results: Twenty-eight (28) cervical cancers were diagnosed and confirmed in the department during the study period, however, twenty-seven (27) of the cases were considered appropriate for HPV detection after histological evaluation and Twenty-five (25) (92.6%) were positive for HPV DNA. The six most common types of HPV occurring recurrently among HPV positive cases were HPV16 (47.1%), HPV35 (11.8%), HPV31 (9.8%), HPV18 (5.9%), HPV45 (3.9%) and HPV58 (3.9%). Multiple infections were detected in 68% of the cases. Conclusion: The high occurrence of HPV type 16 in this study confirms the role of HPV 16 in cervical cancer pathogenesis in the studied population and high rate of multiple infections also suggests that multiple infections play significant role in the pathogenesis of cervical cancer. The findings of high occurrence of HPV 35 as a co-infection with HPV 16 and other types of HPV also suggest that the vaccines currently used as preventive measures against cervical cancer in this environment which offers no prevention against HPV 35, may not prevent majority of invasive cervical cancers in the studied population. |
|
Accepted: 09/11/2021 Published: 15/11/2021 |
|
|
*Corresponding Author Dr Omoseebi Oladipo E-mail: omoseebidipo@ yahoo.com; omoseebio@abuad.edu.ng |
|
|
Keywords: Cervical cancer; Human Papilloma Virus (HPV); Polymerase chain reaction (PCR); Human Papilloma Virus DNA |
|
|
|
|
Return to Content View [Full Article - PDF] |
REFERENCES
1. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87(11): 796-802.
2. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gomez Z, et al. Human Papillomavirus and related diseases report: 2016. ICO Information Centre on HPV and Cancer (HPV Information Centre). Available at: https://www.hpvcentre.net.
3. Muñoz N, Castellsagué X, de González AB, Gissmann L. HPV in the etiology of human cancer. Vaccine. 2006; 24(3): S1–S10.
4. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1): 12–19.
5. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, et al. Cervical HPV infection and neoplasia in a large population‐based prospective study: the Manchester cohort. Br J Cancer. 2004; 91: 942–53.
6. Dalstein V, Riethmuller D, Pretet JL, Le Bail Carval K, Sautiere JL, Carbillet JP, et al. Persistence and load of high‐risk HPV are predictors for development of high‐grade cervical lesions: a longitudinal French cohort study. Int J Cancer. 2003; 106: 396–403.
7. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, et al. Type‐specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med. 1999; 341: 1633– 38.
8. Ferenczy A, Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol. 2002; 3: 11–16.
9. Arbyn M, Castellsagué X, de sanjosé, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011; 22(12): 2675–86.
10. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): 359-86.
11. ICO/IARC Information Center on Human Papilloma Virus and Cancer. Human Papilloma Virus and related diseases in Nigeria. Summary report. 2017. Available at: https://hpvcentre.net/statistics/reports.
12. Murray CJL, Lopez AD. Global Health Statistics. Boston, Harvard School of Public Health on behalf of WHO and the World Bank: 1996. Available at https://apps.who.int/iris/handle.
13. Stewart BW, Kleihues P. WHO Cancer Report. Lyon, France. IARC; Cancers of the female reproductive tract: 2003. pp. 215–222. Available at: https://www.iarc.fr/wcr.
14. Li N, Franceschi S, Howell-Jones R, Snijders PJF. Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011; 128 (4): 927–35.
15. Koutsky LA, Harper DM. Chapter 13: current findings from prophylactic HPV vaccine trials. Vaccine. 2006; 24 (3): S114– S121.
16. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006; 95: 1459-66.
17. Chauhan SC, Jaggi M, Bell MC, Verma M, Kumar D. Epidemiology of human papilloma virus (HPV) in cervical mucosa. Methods Mol Biol. 2009; 471: 439-56.
18. Mbaye EHS, Gheit T, Dem A. Human papillomavirus infection in women in four regions of Senegal. J Med Virol. 2014; 86(2): 248–56.
19. Zohoncon TM, Bisseye C, Djigma F W. Prevalence of HPV high-risk genotypes in three cohorts of women in Ouagadougou (Burkina Faso). Mediterr J Hematol Infect Dis. 2013; 5(1): 1-6.
20. Djigma FW, Ouédraogo C, Karou DS, Sagna T. Prevalence and genotype characterization of human papillomaviruses among HIV-seropositive in Ouagadougou, Burkina Faso. Acta Trop. 2011; 117 (3): 202–6.
21. Ouedraogo CMR, Djigma FW, Bisseye C, Sagna T, Zeba M, Ouermi D, et al. Epidemiology, characterization of genotypes of human papillomavirus in a population of women in Ouagadougou. J Gynecol Obste Biol Reprod. 2011; 40(7): 633-38.
22. Brotherton JML. Impact of HPV vaccination: achievements and future challenges. Papillomavirus Res. 2019; 7: 138–40.
23. Tran NP, Hung CF, Roden R, Wu TC. Control of HPV infection and related cancer through vaccination. Recent Results Cancer Res. 2014; 193: 149–71.
24. Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: A population-based study. Br J Cancer. 2004; 90: 638-45
25. Schnatz PF, Markelova NV, Holmes D, Mandavilli SR, O'Sullivan DM. The prevalence of cervical HPV and cytological abnormalities in association with reproductive factors of rural Nigerian women. J Womens Health (Larchmt). 2008; 17: 279-85.
26. Orah NO, Banjo AAF. Prevalence and distribution of high risk human papillomavirus subtypes in invasive cervical cancer in South-West Nigeria. Ann Trop Pathol. 2018; 9: 106-10.
27. Kolawole OM, Olatunji KT, Durowade KA. Molecular detection of human papilloma Virus from abnormal cervical cytology of women attending a tertiary health facility in Ido-Ekiti, southwest, Nigeria. J Prev Med Hyg. 2016; 57(2): 86–90.
28. Skinner SR, Wheeler CM, Romanowski B. Progression of HPV infection to detectable cervical lesions or clearance in adult women: analysis of the control arm of the VIVIANE study. Int J Cancer. 2016; 138(10): 2428–38.
29. Brianti P, De Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol. 2017; 40(2): 80–5.
30. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol. 2010; 117(2): S5–S10.
31. Mirabello L, Clarke MA, Nelson CW, Dean M, Wentzensen N, Yeager M, et al. The intersection of HPV epidemiology, genomics and mechanistic studies of HPV-mediated carcinogenesis. Viruses. 2018; 10(2): 80.
32. Peedicayil A, Abraham P, Sathish N, John S, Shah K. Sridharan G. Human Papillomavirus genotypes associated with cervical neoplasia in India. Int J Gynecol Cancer. 2006; 16: 1591-1595.
33. de Cremoux P, de la Rochefordière A, Savignoni A, Kirova Y, Alran S, Fourchotte V. Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype. Int J Cancer. 2009; 124:778-782.
34. Odida M, de Sanjosé S, Quint W, Bosch XF, Klaustermeier J, Weiderpass E. Human papillomavirus type distribution in invasive cervical cancer in Uganda. BMC Infect Dis. 2008; 8: 85.
35. Niyazmetova L, Aimagambetova G, Stambekova N, Abugalieva Z, Seksembayeva K, Ali S, et al. Application of molecular genotyping to determine prevalence of HPV strains in Pap smears of Kazakhstan women. Int J Infect Dis. 2017; 54: 85–8.
36. Stanczuk GA, Kay P, Sibanda E, Allan B, Chirara M, Tswana SA, et al. Typing of human papillomavirus in Zimbabwean patients with invasive cancer of the uterine cervix. Acta Obstet Gynecol Scand. 2003; 82: 762-6.
37. Del Mistro A, Salamanca HF, Trevisan R, Bertorelle R, Parenti A, Bonoldi E. Human papillomavirus typing of invasive cervical cancers in Italy. Infect Agents Cancer. 2006; 1: 1-9.
38. Prétet JL, Jacquard AC, Carcopino X, Charlot JF, Bouhour D, Kantelip B, et al. Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study. Int J Cancer. 2008; 122:428-32.
39. el-All HS, Refaat A, Dandash K. Prevalence of cervical neoplastic lesions and human papilloma virus infection in Egypt: National cervical cancer screening project. Infect Agents Cancer. 2007; 2:12.
40. Munagala R, Donà MG, Rai SN, Jenson AB, Bala N, Ghim SJ. Significance of multiple HPV infection in cervical cancer patients and its impact on treatment response. Int J Oncol.2009; 34: 263-271.
41. Lee SA, Kang D, Seo SS, Jeong JK, Yoo KY, Jeon YT. Multiple HPV infection in cervical cancer screened by HPV DNA Chip. Cancer Lett. 2003; 198:187-92.
42. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, ortolero-Luna G, Kjaer SK, Muñoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26(10):1-16.
43. Traore IMA, Zohoncon TM, Dembele A, Djigma FW, Obiri-Yeboah D, Traore G, et al. Molecular characterization of high-Risk human papillomavirus in women in Bobo-Dioulasso, Burkina Faso. Int J BioMed Res. 2016; 2016: 1-6.
44. Ogembo RK, Gona PN, Seymour AJ, Park HS, Bain PA, Maranda L, et al. Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: A systematic review and meta-analysis. PLoS One. 2015; 10: e0122488.
45. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000; 92: 464-74.
46. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367: 1247-55.
47. Sonusi S, Oguntunde O, Banjo A. Histologic patterns of cervical malignancy in Lagos University Teaching Hospital. Am J Clin Pathol. 2018; 150(1): S45-S50.
48. Olu-Eddo AN, Ekanem VJ, Umannah I, Onakevhor J. A 20 year histopathological study of cancer of the cervix in Nigerians. Niger Q J Hosp Med. 2011; 21(2): 149-53.
49. Silas OA, Yakubu D, Jegede OO, Ajetunmobi OI, Mosugu O. A histopathologic review of cervical cancers in Jos University Teaching Hospital, Jos, Nigeria. Ann Trop Pathol. 2018; 9(2): 135-8.
50. Kleter B, van Doorn LJ, ter Schegget J, Schrauwen L, van Krimpen K, Burger M, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol. 1998; 153:1731-39.
51. Sanchez GI, Bravo LE, Hernandez-Suarez G, Tous S, Alemany, L, de Sanjose S. Secular trends of HPV genotypes in invasive cervical cancer in Cali, Colombia, 1950-1999. Cancer Epidemiol. 2016; 40:173-8.
52. Rais M, Kharmoum J, Ech-Charif S, El Khannoussi B. Adenoid cystic carcinoma of the uterine cervix: A Report of 2 Cases. Case Rep Pathol. 2017; 2017: 8401741.
53. Grayson W, Taylor L, Cooper K. Detection of Integrated High Risk Human Papillomavirus in Adenoid Cystic Carcinoma of the Uterine Cervix. J Clin Pathol. 1996; 49(10):805-9.
|
Cite this Article: Omoseebi O; Okiki PA; Obajuluwa AO; Erinomo OO (2021). Genotyping of Human Papilloma Virus (HPV) in Cervical Cancer at the Federal Teaching Hospital Ido-Ekiti, Ekiti State, Nigeria. Greener Journal of Medical Sciences, 11(2): 201-211. |
Call for Papers
Call for Scholarly Articles
Authors from around the world are invited to send scholary articles that suits the scope of this journal. The journal is currently open to submissions and will process and publish articles monthly in two yearly issues.
The journal is centered on quality and goes about its processes in a very timely fashion. Seasoned editors/reviewers will be consulted to review each article(s), profer quality evaluations and polish the articles with expertise before publication.
Simply send your article(s) as an e-mail attachment to manuscripts@acad.gjournals.org or manuscripts.igj@gmail.com.
Advertisements
